Traders bought shares of CVS Health Corp (NYSE:CVS) on weakness during trading on Monday following insider selling activity. $123.07 million flowed into the stock on the tick-up and $79.65 million flowed out of the stock on the tick-down, for a money net flow of $43.42 million into the stock. Of all companies tracked, CVS Health had the 27th highest net in-flow for the day. CVS Health traded down ($0.78) for the day and closed at $78.55Specifically, EVP Troyen A. Brennan sold 14,229 shares of CVS Health stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $82.00, for a total value of $1,166,778.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Lisa Bisaccia sold 21,534 shares of CVS Health stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total value of $1,722,720.00. The disclosure for this sale can be found here. Insiders sold 57,638 shares of company stock worth $4,558,875 in the last 90 days. Company insiders own 0.53% of the company’s stock.

A number of equities research analysts have commented on CVS shares. Royal Bank of Canada set a $99.00 target price on CVS Health and gave the company a “buy” rating in a research report on Tuesday, October 23rd. Morgan Stanley set a $100.00 price objective on CVS Health and gave the company a “buy” rating in a research note on Wednesday, November 7th. Bank of America lifted their price objective on CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Leerink Swann lifted their price objective on CVS Health from $85.00 to $95.00 and gave the company a “positive” rating in a research note on Thursday, November 8th. Finally, ValuEngine raised CVS Health from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. CVS Health presently has an average rating of “Buy” and a consensus price target of $90.04.

The company has a market cap of $80.82 billion, a price-to-earnings ratio of 13.31, a price-to-earnings-growth ratio of 1.06 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 2.44 and a debt-to-equity ratio of 1.66.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.71 by $0.02. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The firm had revenue of $47.27 billion during the quarter, compared to analysts’ expectations of $47.22 billion. During the same period in the previous year, the firm posted $1.50 EPS. CVS Health’s revenue for the quarter was up 2.4% on a year-over-year basis. Research analysts predict that CVS Health Corp will post 7.03 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Wednesday, October 24th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, October 23rd. This represents a $2.00 annualized dividend and a yield of 2.55%. CVS Health’s payout ratio is 33.90%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Camarda Financial Advisors LLC acquired a new position in CVS Health during the 2nd quarter worth $102,000. Kiley Juergens Wealth Management LLC acquired a new position in CVS Health during the 2nd quarter worth $103,000. Squar Milner Financial Services LLC acquired a new position in CVS Health during the 2nd quarter worth $122,000. Canton Hathaway LLC acquired a new position in CVS Health during the 3rd quarter worth $126,000. Finally, MCF Advisors LLC grew its stake in CVS Health by 284.1% during the 3rd quarter. MCF Advisors LLC now owns 1,713 shares of the pharmacy operator’s stock worth $135,000 after purchasing an additional 1,267 shares in the last quarter. 83.03% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/11/19/traders-buy-shares-of-cvs-health-cvs-on-weakness-on-insider-selling.html.

CVS Health Company Profile (NYSE:CVS)

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.